Swiss Commercial Services Stock News

Idorsia Ltd recently reported half-year 2026 results showing revenue of CHF 110.25 million, a shift from net income to a net loss, while reaffirming full-year sales guidance of CHF 200 million. At the same time, Idorsia entered an exclusive agreement with Jamjoom Pharmaceuticals to distribute and commercialize its insomnia treatment QUVIVIQ across Saudi Arabia and the Levant, adding a new regional partner and revenue stream structure built on upfront, milestone, and royalty payments. Next,...

Medacta Group revenue update and why it matters for investors Medacta Group (SWX:MOVE) reported unaudited first half 2026 revenue of €368 million, compared with €344 million a year earlier. This fresh trading statement is drawing attention to how the stock’s recent performance lines up with its underlying business trends. See our latest analysis for Medacta Group. Despite the latest revenue update, Medacta Group’s share price has weakened over 2026, with a year to date share price return of...

In August 2026, ams-OSRAM reported second-quarter results showing sales of €805 million alongside a net loss of €122 million, and issued guidance for third-quarter revenues between €770 million and €870 million while signalling slightly lower full-year 2026 revenue due to divestments and foreign exchange effects. An important implication is that modest year-on-year revenue softening is driven not only by operating conditions but also by portfolio reshaping and currency headwinds, which...

Why ABB Stock Is In Focus After The LevelTen Energy Deal ABB (SWX:ABBN) has put its energy and carbon advisory business in the spotlight after announcing a partnership and minority investment in LevelTen Energy, the clean energy marketplace and software platform. See our latest analysis for ABB. ABB shares trade at CHF81.76 after easing 0.68% on the day, while the share price return since the start of the year is up 33.51% and the 5 year total shareholder return of 176.72% points to strong...

Amrize stock has been grinding lower for weeks, down about 7% over the past three months. Yet Q2 landed with the kind of earnings snap that makes short term price action look impatient. The company delivered basic earnings per share of US$0.87 on revenue of US$3.5b, a clean rebound from the loss in Q1. That profit swing is now feeding into a bigger question for you as a shareholder: Is this the start of a more durable earnings run that eventually forces the market to reassess Amrize’s...

GAM Holding’s stock has been grinding higher in recent weeks, with the share price at CHF0.0828 after a strong 7 day and 30 day run. The quick win on the screen is only half the story. The fresh H1 2026 numbers highlight why this is still a high risk turnaround. The headline is the continuing earnings strain. GAM reported a loss of CHF58.2 million over the trailing twelve months on revenue of CHF48.8 million. The market sees a low P/S multiple and recent price momentum, but the key question...

Zurich Insurance Group shares came into these results slightly on the back foot after a modest slide over the past week, yet the latest half year numbers tell a more upbeat story. Business operating profit reached about US$4.8b and core earnings per share rose in the low double digits. Every major business line contributed, which matters far more to the long term thesis than a soft recent chart. The key tension for you as an investor is simple. The stock price is hesitating while the earnings...

The market has been steadily warming to Adecco Group in recent weeks, with the stock up about 46% over the past month. Today’s earnings, however, offer a cooler reality check. Revenue for the quarter sits at €5,997m, while basic earnings per share come in at €0.27, both solid but not especially rapid for a staffing heavyweight. The key issue is the tension between valuation and relatively thin profitability. Adecco trades on a trailing P/E of 15x and carries a net profit margin of 1.3%. The...

OC Oerlikon stock comes into this earnings day on a tear, up about 36% over the past three months, which sets a high bar for any result. The headline this time is not about eye catching revenue growth; it is about margins. Operational EBITDA of CHF 156m in the first half with a 19.7% margin and a 300 basis point expansion has turned the spotlight onto profitability rather than top line noise. The question now is whether that margin story fully justifies the recent re rating or whether short...

Galenica just served up earnings that look stronger than the recent share price would suggest. The stock closed at CHF82.2 on 7 August, with the past month and quarter both in slightly negative territory. Yet underneath that soft chart sits a healthcare retailer and distributor that reported H1 2026 sales of CHF2.143b and an adjusted earnings before interest and taxes margin in its Products & Care arm that edged higher. For a company often viewed as a dependable Swiss healthcare utility, the...

Swisscom stock heads into this earnings reaction priced for caution rather than excitement. The share price is roughly flat over the past week and month, and it has slipped about 6% over the last quarter, even as the company trades on a relatively rich trailing P/E of 24.8x. The headline from this quarter is not revenue movement. It is the profit squeeze. Net margin on a trailing basis now sits at 8.9%, lower than 10.2% a year earlier, even as management leans on Italian synergies and Swiss...

Swiss Re stock closed at CHF138.50, capping a solid 90 day run that left holders already sitting on a double digit gain before these results hit the tape. The headline today is simple. The market is reacting to a reinsurer that has already booked US$2.8b in net income for the first half of 2026 and a 23% return on equity. For short term traders, the question is how much of that strength is already priced in. For long term investors, the focus shifts to what those earnings and margins say...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

EMS-CHEMIE HOLDING AG ( VTX:EMSN ) is about to trade ex-dividend in the next 3 days. The ex-dividend date is commonly...

It's been a pretty great week for ams-OSRAM AG ( VTX:AMS ) shareholders, with its shares surging 12% to CHF17.61 in the...

Investors were underwhelmed by the solid earnings posted by Logitech International S.A. ( VTX:LOGN ) recently. We did...

Sandoz Group shareholders walked into this earnings day with a stock that had inched higher over the past week but gone essentially sideways over the past month. The market is still trying to decide whether a rich P/E of 57.2x belongs on a generics and biosimilars specialist or on a high growth story that just happens to sell off patent drugs. H1 2026 results gave that debate fresh fuel. Net sales reached about US$5.8b with a core earnings before interest, tax, depreciation and amortisation...

In recent weeks, the European market has shown resilience, with the STOXX Europe 600 Index reaching new highs driven by robust corporate earnings and a recovery in sentiment toward AI-related stocks. As investors navigate these dynamic conditions, dividend stocks present an appealing option for those seeking stable income streams and potential growth opportunities amidst economic fluctuations.

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Vontobel Holding (SWX:VONN) has drawn fresh investor attention after reporting half year 2026 results on 24 July, with higher net interest income and net income than in the same period a year earlier. See our latest analysis for Vontobel Holding. At a share price of CHF85.90, Vontobel Holding has seen strong recent momentum, with a 30 day share price return of 11.85% and a year to date share price return of 30.15%. The 1 year total shareholder return of 50.68% and 3 year total shareholder...

Roche Holding (SWX:ROP) has seen fresh attention after the U.S. FDA granted 510(k) clearance for its cobas BV/CV molecular assay. This clearance expands the company’s diagnostics menu in vaginal and broader sexual health testing. See our latest analysis for Roche Holding. Alongside the new cobas BV/CV assay, Roche Holding’s share price is at CHF364.70, with a 30-day share price return of 9.92% and a 1-year total shareholder return of 51.19%, indicating that momentum has been building despite...

Avolta (SWX:AVOL) is in focus after its half year 2026 earnings update showed lower sales and revenue than a year earlier, alongside higher net income and earnings per share from continuing operations. See our latest analysis for Avolta. Avolta’s share price closed at CHF49.44 on 30 July, with a 90 day share price return of 9.72% and a year to date share price return of 5.69%. The 1 year total shareholder return of 19.55% and 3 year total shareholder return of 27.03% point to momentum that...

Partners Group Holding (SWX:PGHN) is drawing attention after an AI transformation program at portfolio company Foundation Risk Partners reportedly lifted EBITDA margin by 120 bps and shortened policy processing times. See our latest analysis for Partners Group Holding. Against this backdrop, Partners Group Holding’s recent AI driven value creation sits alongside a share price that has risen 3.4% over the past week and 5.8% over the past month. However, the share price remains down 30.4% year...

SGS (SWX:SGSN) drew fresh attention after releasing its half year 2026 results, reporting sales of CHF 3,683 million and net income of CHF 309 million, alongside slightly lower earnings per share than a year earlier. See our latest analysis for SGS. Since the July earnings release, SGS has seen momentum build, with a 12.05% 90 day share price return and a 23.20% 1 year total shareholder return at a latest share price of CHF 98.04. If the SGS update has you thinking about where else growth and...